158
Participants
Start Date
April 13, 2022
Primary Completion Date
June 1, 2025
Study Completion Date
October 1, 2025
LSTA1
LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
Gemcitabine Injection
Chemotherapy drug provided as solution to be administered via IV infusion.
Nab paclitaxel
Chemotherapy drug provided as solution to be administered via IV infusion.
Sunshine Coast University Hospital, Birtinya
Chris O'Brien Lifehouse, Camperdown
St George Hospital, Kogarah
Lake Macquarie Private Hospital, Gateshead
Border Medical Oncology, Albury
The Alfred Hospital, Melbourne
Northern Health, Epping
Warringal Private Hospital, Heidelberg
Epworth Healthcare, Richmond
Monash Medical Centre, Clayton
Royal Brisbane and Womens Hospital, Herston
Icon Cancer Centre Wesley, Auchenflower
ICON Cancer Centre, Gold Coast University Hospital, Southport
Queen Elizabeth Hospital, Woodville South
St John of God, Subiaco
Fiona Stanley Hospital, Murdoch
Calvary Mater Newcastle, Newcastle
Newcastle Private Hospital, Newcastle
Prince of Wales Hospital, Sydney
Flinders Medical Centre, Adelaide
Launceston General Hospital, Launceston
Frankston Hospital, Melbourne
Dunedin Hospital, Dunedin
Waikato Hospital, Hamilton
University of Sydney
OTHER
Australasian Gastro-Intestinal Trials Group
NETWORK